FIGURE 4.
Diseases in which activators of ALDH2 may be beneficial. See text for full discussion. Red highlights diseases where the evidence for ALDH2 role came from preclinical proof-of-concept studies. Blue highlights diseases where ALDH2 role was supported by clinical observations. Black highlights diseases where evidence from both preclinical studies and from human epidemiological or pathohistological studies supports a role for ALDH2.